Company lists · Data refreshed September 2026
Top 25 Neurological disorder drug developers based in the United States
RevenueBase identified 319 neurological disorder drug developers headquartered in the United States as of September 2026 and tracks 11,320 professional contacts across them, including 5,343 with verified work emails. Boston is the largest hub.
This list covers neurological disorder drug developers headquartered in the United States, matched on what each company actually does as described in its own words. Ranked by team size, largest first. Every row shows the company's own description, its RevenueBase Smart Search rating, and when it was last checked. Data refreshed September 20, 2026.
Published by RevenueBase, a B2B data infrastructure company. This list was built with RevenueBase Smart Search, the natural-language company search RevenueBase customers use to build their own targeted lists and unlock verified emails and direct dials at the companies on them. How these lists are built and judged.
The 25 largest neurological disorder drug developers based in the United States
Ranked by team size| # | Company | Contacts | |||
|---|---|---|---|---|---|
| 1 | 1,971 contacts → | ||||
Indirect evidence “Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs.” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 2 | 910 contacts → | ||||
Strong evidence “At Acadia, our mission is to turn scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 3 | 801 contacts → | ||||
Indirect evidence “Supernus Pharmaceuticals, Inc.(the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS)…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 4 | 785 contacts → | ||||
Indirect evidence “Intra-Cellular Therapies, Inc, a Johnson & Johnson company, is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand how therapies…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 5 | 346 contacts → | ||||
Partial evidence “Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 6 | 293 contacts → | ||||
Indirect evidence “Corium is a commercial-stage biopharmaceutical company advancing novel neuroscience therapies that provide clinicians with important treatment options for patients, their…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 7 | 292 contacts → | ||||
Partial evidence “Harmony Biosciences is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative therapies for people living with rare and other neurological…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 8 | 229 contacts → | ||||
Partial evidence “Acorda Therapeutics is a publicly traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 9 | 208 contacts → | ||||
Indirect evidence “Voyager Therapeutics, Inc.(Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure –…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 10 | 203 contacts → | ||||
Indirect evidence “Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 11 | 192 contacts → | ||||
Partial evidence “We are a late-stage clinical biotechnology company with a mission to make degenerative brain disorders history.” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 12 | 177 contacts → | ||||
Partial evidence “Neurelis, Inc, is dedicated to innovating life-changing therapeutics that help people with neurological conditions gain greater control over their journeys.” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 13 | 116 contacts → | ||||
Partial evidence “Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 14 | 110 contacts → | ||||
Indirect evidence “Aytu BioPharma (NASDAQ: AYTU) is a dynamic & growing specialty biopharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS)…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 15 | 109 contacts → | ||||
Partial evidence “Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families.” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 16 | 87 contacts → | ||||
Strong evidence “Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 17 | 83 contacts → | ||||
Indirect evidence “Brain diseases collectively represent one of the largest areas of unmet medical need, affecting upwards of 1.5 billion patients globally.” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 18 | 82 contacts → | ||||
Indirect evidence “Eisai U.S.” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 19 | 69 contacts → | ||||
Indirect evidence “Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 20 | 66 contacts → | ||||
Partial evidence “At Kallyope, we are leveraging unique insights into neural signaling pathways and developing innovative medicines for the treatment of migraine and metabolic disorders.” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 21 | 65 contacts → | ||||
Indirect evidence “Clene Inc,(Nasdaq: CLNN)(along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc, is a late clinical-stage biopharmaceutical company focused…” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 22 | 65 contacts → | ||||
Partial evidence “Remepy is Pioneering Hybrid Drugs™.” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 23 | 65 contacts → | ||||
Indirect evidence “Karuna Therapeutics, Inc.” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 24 | 64 contacts → | ||||
Indirect evidence “Atalanta Therapeutics is a biotechnology company developing treatments for intractable diseases of the central nervous system using RNA interference.” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
| 25 | 63 contacts → | ||||
Indirect evidence “Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance.” Source: RevenueBase Database · checked Sep 20, 2026Thanks. The Data Team will review it. | |||||
RevenueBase Smart Search
RevenueBase Smart Search assesses information from a company’s LinkedIn profile, information supplied directly by the company, its website, and other publicly available sources. It uses that information to rate how closely the company relates to this list’s category: neurological disorder drug developers. Every row carries its rating and the description the rating was read from, so each one can be checked rather than taken on trust.
- Strong evidence
- The company's own public description of its business names neurological disorder drug developers.
- Partial evidence
- Its own public description names part of neurological disorder drug developers, so it works in or next to the category without describing itself that way.
- Indirect evidence
- The description shown does not name neurological disorder drug developers. The match rests on the rest of the company's public profile rather than the one sentence quoted here, so this is the rating to check first.
RevenueBase Smart Search is how these lists are built: RevenueBase's data engine and AI assemble the companies that match a category defined in a user's own words, so a list can be about what companies actually do rather than about whichever industry code they were filed under.
Showing 25 of 319 neurological disorder drug developers based in the United States
See the full list, filter by size, metro and specialty, and get verified emails and direct dials for all 5,343 reachable decision-makers.
Free signup · no credit card
Neurological disorder drug developers based in the United States at a glance
As of Sep 20, 2026Companies by employee count
Email recency for this list is measured worldwide rather than for United States, so it is reported there. Company counts and contact totals on this page are exact for United States, over 319 companies.
How this list was built
Company categories are rarely black and white. RevenueBase reads each company's own description of its business to decide whether it belongs among neurological disorder drug developers, so some rows will be adjacent to the category rather than pure plays. The description and RevenueBase Smart Search rating on every row are there so you can check each match yourself.
- Source
- The RevenueBase company graph: 60 million companies and 398.9 million professional contacts resolved from primary sources, queried with RevenueBase Smart Search, the natural-language company search available to every RevenueBase user.
- What qualifies
- Companies headquartered in the United States whose own description of what they do matches “neurological disorder drug developers”. Matching reads each company's description, not its industry code or its name.
- RevenueBase Smart Search
- RevenueBase Smart Search is how this list is assembled and how each row is rated. RevenueBase's data engine and AI assess a company's LinkedIn profile, information supplied directly by the company, its website and other publicly available information, then relate it to a category defined in a user's own words. Each row is rated strong evidence (its own description names neurological disorder drug developers), partial evidence (it names part of the category) or indirect evidence (the description shown names none of it and the match rests on the rest of the company's profile). The description supporting each rating is quoted on the row.
- What we exclude
- Companies whose own description does not clearly place them among neurological disorder drug developers, and records with no verified work email. Companies headquartered outside United States are excluded even when they keep an office there.
- Match quality
- In blind human judging of this matching method, 86% of matched companies were on target. Expect roughly 1 in 7 rows to be adjacent to the category rather than a pure play. Every row shows the company's own description and its RevenueBase Smart Search rating so you can judge each match yourself. Read the full methodology: how the lists are built, how the judging worked, and what the figure means.
- Ranking
- Team size, largest first: companies are ordered by the number of professionals RevenueBase tracks at each one. Employee ranges shown are reported bands, for context.
- Verification
- Every listed company carries at least one verified work email, 5,343 across the full list. Contacts re-verify on a rolling cadence, and each contact's own verification date is shown inside RevenueBase.
- Refresh
- This page's figures were pulled from the company graph on September 20, 2026. Lists refresh periodically as the graph is re-checked.
- Corrections
- Wrong category, wrong headquarters, or a company that has closed? Use “Report an issue” on any row. Reports go to the RevenueBase Data Team and feed back into the company graph.
Frequently asked
What is RevenueBase Smart Search?
RevenueBase Smart Search is how RevenueBase decides which companies belong on this list and how strongly each one fits. Its data engine and AI assess a company's LinkedIn profile, information supplied directly by the company, its website and other publicly available information, then relate it to the category the list is about. Each row is rated strong evidence when the company's own description names neurological disorder drug developers, partial evidence when it names part of the category, and indirect evidence when the description shown names none of it and the match rests on the rest of the company's profile.
How many neurological disorder drug developers are there based in the United States?
RevenueBase identified 319 neurological disorder drug developers headquartered in the United States as of September 2026, matched on each company's own description of what it does rather than its industry code.
What is the largest company on this list?
Neurocrine Biosciences, headquartered in San Diego, tops this list with the largest team on record.
Which city has the most neurological disorder drug developers?
Boston leads with 22 headquartered companies, followed by New York (20) and Cambridge (14).
How do I get contact information for these companies?
A free RevenueBase account lets you run this exact search and work the top results, verified emails and direct dials included. Upgrading unlocks all 5,343 verified decision-maker contacts tracked across these 319 companies.
How current is this list?
The list refreshes periodically as the company graph is re-checked. This page's figures were pulled on September 20, 2026.
Ready to reach these companies? Verified emails and direct dials for all 319 neurological disorder drug developers based in the United States. Start with a free account, no credit card.
Download this list →Related lists
Neurological disorder drug developers by geography
About this data
RevenueBase is a B2B data infrastructure company. Its company graph covers 60 million companies and 398.9 million professional contacts, with emails verified on a rolling cadence rather than scraped once and left to decay. These company lists are generated directly from that graph with RevenueBase Smart Search, the same natural-language company search every RevenueBase user has: describe a market in plain words, get the companies that match, and add verified emails and direct dials for the people at them. It is the same data that powers RevenueBase's B2B data products, and a free account includes 500 credits to start. How these lists are built and judged.
More company lists
- All company lists
- Lists by location
- Lists A-Z
- New lists
- Neurological disorder drug developers based in Canada
- Neurological disorder drug developers based in the United Kingdom
- AI companies based in the United States
- Cybersecurity companies based in the United States
- Manufacturing companies based in the United States
- Media companies based in the United States